





Supplementary Figure 2. Mastoparan is a direct-acting ACP in breast cancer cells. (A) MDA-MB-231 breast cancer cells were treated with vehicle control (filled peak) or 50 μM Mastoparan (open peak) for 5 or 10 min. Membrane damage was assessed by propidium iodide uptake. Data shown are from a representative experiment (n=3). Values indicate mean channel fluorescence. (B) MDA-MB-231 breast cancer cells pretreated with the pancaspase inhibitor BOC-D-FMK or the vehicle control, were cultured in the presence or absence of the indicated concentrations of Mastoparan. Cytotoxicity was assessed by MTT assay after 24 h. Data shown represent the mean of 3 independent experiments ± SEM. (C) MDA-MB-231 cells cultured under the indicated conditions were fixed, stained with DAPI, and were visualized (40x) by UV microscopy. Paclitaxel is included as a positive control for apoptosis. Data shown are from a representative experiment (n=3).